Hyperfine, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Maria Degois Sainz
- Full Time Employees
- 102
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Address
- 351 New Whitfield Street Guilford CT United States of America 06437
- IPO Date
- Jan 28, 2021
- CIK
- 0001833769
- Website
- hyperfinemri.com
- Similar Companies
- Business
- Hyperfine, Inc. (Nasdaq: HYPR) develops, manufactures, and commercializes portable magnetic resonance imaging (MRI) systems for point-of-care brain imaging; its flagship Swoop Portable MR Imaging System, powered by Optive AI software, operates at ultra-low field strength (0.064T) to produce diagnostic-quality images including T1, T2, FLAIR, and DWI sequences in axial, coronal, and sagittal planes without requiring specialized infrastructure or shielding; the company also provides Hyperfine Image Viewer cloud platform for image archiving and management, technical support services, and software updates. Founded in 2014 by Jonathan Rothberg and headquartered in Guilford, Connecticut, Hyperfine targets hospitals (ICUs, emergency departments, neurology), clinics, pediatrics, stroke centers, and research institutions with its wheeled, AI-enhanced systems that enable bedside scanning globally. In 2025, Hyperfine secured FDA clearance and launched commercial sales of its next-generation Swoop system with Optive AI for substantially improved image quality; introduced the PULSE platform to accelerate AI-powered MRI adoption; announced first patient enrollments in PRIME, PRISM PMR, and NEURO PMR clinical studies evaluating portable MRI in emergency departments, operating rooms, and neurology offices; received a $3.7 million grant for global brain health initiatives and a CE Mark/UKCA approval for Optive AI to expand in Europe; expanded distribution partnerships in Turkey, Israel, Saudi Arabia, India, and additional European/Middle Eastern markets; and completed $17.5 million and $6.0 million offerings to support commercialization, manufacturing, and R&D.
Hyperfine Announces European Launch of Next-Generation Swoop® System
Hyperfine Forms Global Neurosurgery Advisory Council to Support Expansion of Portable MRI in Neurosurgical Care
Hyperfine Swoop® System Scan Volume in the United States Hits Record Milestones Across Multiple Sites of Care
Hyperfine Swoop® System Scan Volume in the United States Hits Record Milestones Across Multiple Sites of Care
Hyperfine, Inc. (HYPR) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Hyperfine to Join Russell 2000® and Russell 3000® Indexes
Hyperfine to Join Russell 2000® and Russell 3000® Indexes
Hyperfine Announces Presentation of Results from the PRIME Study Showing Portable MRI Substantially Reduces Time to Imaging in Emergency Departments
Hyperfine, Inc. (HYPR) Q1 2026 Earnings Call Transcript
Hyperfine Q1 Earnings Call Highlights
Hyperfine, Inc. (HYPR) Reports Q1 Loss, Beats Revenue Estimates
Hyperfine, Inc. Reports First Quarter 2026 Financial Results
Hyperfine, Inc. to Participate in Upcoming 2026 Jefferies Global Healthcare Conference
Hyperfine Swoop® System Introduced as India's First Portable MRI for Bedside Brain Imaging at the Country's Leading Medical Institution
Hyperfine, Inc. to Announce First Quarter 2026 Financial Results on May 12, 2026
Forget Neuralink: The Real Brain Tech Trade Has 10 Names You’ve Never Heard
Hyperfine Receives CE and UKCA Marks for Next-Generation Swoop® System and Latest Advancement in Optive AI™ Software
How Decentralized AI is Unlocking Value in Cardiac Diagnostics
Horizon Technology Finance Provides $40 Million Loan Facility to Hyperfine
Hyperfine (NASDAQ:HYPR) and Atossa Genetics (NASDAQ:ATOS) Critical Comparison